At the time of writing, Lexeo Therapeutics Inc [LXEO] stock is trading at $10.01, up 6.15%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LXEO shares have gain 8.45% over the last week, with a monthly amount glided 49.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexeo Therapeutics Inc [NASDAQ: LXEO] stock has seen the most recent analyst activity on October 15, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $30. Previously, Oppenheimer started tracking the stock with Outperform rating on July 31, 2025, and set its price target to $20. On June 13, 2024, Robert W. Baird initiated with a Outperform rating and assigned a price target of $28 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $22 on June 06, 2024. Stifel initiated its recommendation with a Buy and recommended $20 as its price target on November 28, 2023. RBC Capital Mkts started tracking with a Outperform rating for this stock on November 28, 2023, and assigned it a price target of $22. In a note dated November 28, 2023, Leerink Partners initiated an Outperform rating and provided a target price of $19 on this stock.
For the past year, the stock price of Lexeo Therapeutics Inc fluctuated between $1.45 and $11.72. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Lexeo Therapeutics Inc [NASDAQ: LXEO] shares were valued at $10.01 at the most recent close of the market. An investor can expect a potential return of 99.8% based on the average LXEO price forecast.
Analyzing the LXEO fundamentals
Gross Profit Margin for this corporation currently stands at -0.28% with Operating Profit Margin at -63.49%, Pretax Profit Margin comes in at -58.73%, and Net Profit Margin reading is -58.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -0.95 and Total Capital is -0.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.51 points at the first support level, and at 9.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.30, and for the 2nd resistance point, it is at 10.59.
Ratios To Look Out For
It is important to note that Lexeo Therapeutics Inc [NASDAQ:LXEO] has a current ratio of 4.43. Also, the Quick Ratio is 4.43, while the Cash Ratio stands at 1.12.
Transactions by insiders
Recent insider trading involved See Tai Sandi, Chief Development Officer, that happened on Oct 17 ’25 when 3888.0 shares were sold. Chief Legal Officer, Robertson Jenny completed a deal on Oct 17 ’25 to sell 3526.0 shares. Meanwhile, Chief Technical Officer Otero Jose Manuel sold 2115.0 shares on Oct 17 ’25.
